Cardiac glycoside specifically categorized based on the plant they are derived from, as in the following list. For example, cardenolides have been primarily derived from the foxglove plants "Digitalis purpurea" and "Digitalis lanata", while bufadienolides have been derived from the venom of the cane toad "Bufo marinus", from which they receive the “bufo” portion of their name. Below is a full list of plants from which cardiac glycosides can be derived. Cardiac glycosides affect the sodium-potassium ATPase pump in cardiac muscle cells to alter their function. Normally, these sodium-potassium pumps move potassium ions in and sodium ions out. Cardiac glycosides, however, inhibit
New Drug Application Review should complete within 6 months. The decision comes in a "Complete Response Letter". Biologics, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a Biologic License Application (BLA), rather than an NDA. The manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process. Generic drugs that have already been approved via an NDA submitted by another maker are approved via an Abbreviated New Drug Application (ANDA), which does not require all of the clinical trials normally required for a new drug